一、导师基本情况
姓名：张轶雯，药理学博士，教授（硕士生导师）
办公电话：0571-88162438（如不便公布可不填写）
邮箱：zhangyiwen@hmc.edu.cn
指导专业（按照招生目录上的名称填写）：药理学
导师单位：浙江省人民医院
二、研究领域
1. 肿瘤药理学
2. 临床药理学
三、主讲课程
《新药研究与开发》
四、教育和工作经历
2020年1月-至今，浙江省人民医院，药学部副主任/临床研究机构办公室副主任
2014年9月-2019年12月，中国科学院大学附属肿瘤医院，药剂科，副主任药师
2015/04–2015/07，北京大学药学院，定量药理学，进修访问
2010/09–2014/06，中南大学湘雅医学院，临床药理学，博士
2007/09–2010/06，沈阳药科大学，天然药物化学，硕士
2003/09–2007/06，浙江中医药大学，中药学，学士
五、学术简介（限200字内）
主要从事肿瘤药理和临床药理方向研究，2020年入选浙江省医坛新秀培养对象。目前已主持国家自然科学基金、浙江省自然科学基金、浙江省中医药管理局重点项目等各类课题10项，以第一作者/通讯作者（含共同）发表论文36篇，其中SCI论文20篇（其中影响因子10以上3篇），参编著作1部，申请专利5项。现为中国抗癌协会青年理事，浙江省医学会临床药学分会委员，浙江省医学会临床试验与伦理分会委员，浙江省药学会专业委员会药物毒理专委会委员，《American Journal of Health-System Pharmacy》学术编辑，《中国现代应用药学》杂志青年编委。
六、主持教学科研项目（省部级以上）
1. 国家自然科学基金青年项目，冬凌草甲素调控PXR-CYP3A4通路介导的胆汁淤积性肝损伤保护作用的研究，2016/01-2018/12
2. 浙江省自然科学基金，肿瘤相关成纤维细胞释放外泌体传递 lncRNA NEAT1 介导肝癌索拉非尼耐药的机制研究，2020/01-2022/12.
七、代表性论著
1. Zhang Y, Lu L, Song F, Zou X, Liu Y, Zheng X, Qian J, Gu C, Huang P, Yang Y. Research progress on non-protein-targeted drugs for cancer therapy. Journal of Experimental & Clinical Cancer Research. 2023 Mar 14;42(1):62.
2. Liu Y, Wang J, Hu X, Pan Z, Xu T, Xu J, Jiang L, Huang P, Zhang Y*, Ge M*. Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy. Drug Resistance Updates. 2023 May;68:100939.
3. Zou X, Liu T, Huang Z, Zhou W, Yuan M, Zhao H, Pan Z, Chen P, Shao Y, Hu X, Zhang S, Zheng S, Zhang Y*, Huang P*. SOX17 is a Critical Factor in Maintaining Endothelial Function in Pulmonary Hypertension by an Exosome-Mediated Autocrine Manner. Advanced Science. 2023 Mar 15:e2206139.
4. Wang Q, Tan Z, Zheng C, Wang J, Zheng G, Huang P, Zhang Y*, Ge M*. Number of Positive Lymph Nodes Combined with the Logarithmic Ratio of Positive Lymph Nodes predicts Survival in Patients with Non-Metastatic Larynx Squamous Cell Carcinoma. Journal of Cancer. 2022 Mar 14;13(6):1773-1784.
5. Lou Y, Qin H, Hu Q, Chai Y, Zhou H, Chen M, Wang Q, Huang P, Gu J, Zhang Y. Development and validation of a novel LC-MS/MS method for simultaneous quantitative determination of tyrosine kinase inhibitors in human plasma. Journal of Chromatography. B. 2022 Oct 1;1208:123394.
6. Guo D, Liu Y, Jiang Y, Zheng S, Xu T, Zhu J, Chen P, Huang P, Zhang Y. A narrative review of the emerging role of lymphocyte antigen 6 complex locus K in cancer: from basic research to clinical practice. Annals of Translational Medicine. 2022 Jan;10(1):26.
7. Zhang Y, Liu Y, Hu X, Song F, Zheng S, Zheng X, Sun J, Li L, Huang P. Stemness-associated senescence genes as potential novel risk factors for papillary renal cell carcinoma. Translational Andrology and Urology. 2021 Nov;10(11):4241-4252.
8. Jiang Y, Song F, Hu X, Guo D, Liu Y, Wang J, Jiang L, Huang P, Zhang Y. Analysis of dynamic molecular networks: the progression from colorectal adenoma to cancer. Journal of Gastrointestinal Oncology. 2021 Dec;12(6):2823-2837.
9. Wan Z, Guo L, Li P, Zhao Z, Xu B, Ren L, Yan Y, Liu H, Zhang Y*, Liu L*. Determinants of gefitinib pharmacokinetics in healthy Chinese male subjects: A pharmacogenomic study of cytochrome p450 enzymes and transporters. Journal of Clinical Pharmacy and Therapeutics. 2020 Oct;45(5):1159-1167.
10. Liu Y#, Zhang Y#, Zheng S, Zheng XC, Ding HY, Xin WX, Sun J, Li L, Huang P. Botrychium schaffneri Underw. extract acts via DIABLO to induce apoptosis and inhibit proliferation of non-small cell lung carcinoma in vitro and in vivo. Ann Transl Med. 2021 Nov;9(22):1676.
11. Song F#, Zhang Y#, Pan Z, Hu X, Yi Y, Zheng X, Wei H, Huang P. Identification of novel key genes associated with the metastasis of prostate cancer based on bioinformatics prediction and validation. Cancer Cell Int. 2021; 21(1): 559.
12. Qin H#, Zhang Y#, Lou Y, Pan Z, Song F, Liu Y, Xu T, Zheng X, Hu X, Huang P. Overview of PROTACs Targeting the Estrogen Receptor: Achievements for Biological and Drug Discovery. Curr Med Chem. 2022; 29(22): 3922-3944.
13. Song F#, Zhang Y#, Pan Z, Hu X, Zhang Q, Huang F, Ye X, Huang P. The role of alcohol dehydrogenase 1C in regulating inflammatory responses in ulcerative colitis. Biochem Pharmacol. 2021 Oct;192:114691.
14. Zhang Y, Bao M, Hu L, Qu Q, Zhou HH. Dose-response of oridonin on hepatic cytochromes P450 mRNA expression and activities in mice. J Ethnopharmacol. 2014; 155(1): 714-20.
15. Zhang Y, Zheng X, Liu Y, Fang L, Pan Z, Bao M, Huang P. Effect of Oridonin on Cytochrome P450 Expression and Activities in HepaRG Cell. Pharmacology. 2018; 101(5-6): 246-254.
16. Zheng X#, Zhang Y#, Liu Y, Fang L, Li L, Sun J, Pan Z, Xin W, Huang P. HIF-2α activated lncRNA NEAT1 promotes hepatocellular carcinoma cell invasion and metastasis by affecting the epithelial-mesenchymal transition. J Cell Biochem. 2018 Apr;119(4):3247-3256.
17. Zhang Y, Bao M, Lou X, Yu C, Jing Y, Zhou H. Effects of Oridonin on Hepatic Cytochrome P450 Expression and Activities in PXR-Humanized Mice. Biol Pharm Bull. 2018; 41(5): 707-712.
18. Zhang Y, Bao M, Wang G, Qu Q, Zhou HH. Induction of human CYP3A4 by huperzine A, ligustrazine and oridonin through pregnane X receptor-mediated pathways. Pharmazie. 2014; 69(7): 532-6.
19. Bao M#, Zhang Y#, Lou X, Xiao Y, Cheng Y, Zhou HH. Puerarin protects endothelial cells from oxidized low density lipoprotein induced injuries via the suppression of LOX-1 and induction of eNOS. Can J Physiol Pharmacol. 2014; 92(4): 299-306.
20. Zheng X#, Ren L#, Zhang Y#, Yin WJ, Tao G, Xin WX, Chen ZJ, Huang P. Subcutaneous tuberculosis formation during FOLFIRI and bevacizumab treatment: a case report. Int J Colorectal Dis. 2016; 31(4): 943-944.
八、成果奖励（省部级以上）
九、授权专利及转化（如无可不填）
2.一种清肺药物组合物及其制备方法，发明专利，申请号: CN202010874175.0
3.一种同时测定清肺药物中多种活性成分的检测方法，发明专利，CN202010874625.6
4. 一种中药组合物及其用途，发明专利，CN202010868259.3
5.一种靶向结合CD133蛋白的核酸适配体药物偶联物及其用途，发明专利，CN 201811484364.6